Biocon enters into a licensing agreement with DKSH

Under this agreement, DKSH will sell and distribute seven of Biocon Pharma′s generic formulations in Singapore and Thailand.

Bio-technology major Biocon signed an agreement with Swiss market expansion services group Diethelm Keller Siber Hegner (DKSH) for distribution of seven generic products in Singapore and Thailand.

Biocon Pharma Ltd, a subsidiary of the bio-technology firm, and DKSH Business Unit Healthcare, have inked an agreement in this regard, Biocon said in a statement.

Under the agreement, DKSH will gain an exclusive license to register and commercialise the seven generic formulations from various therapeutic areas like diabetology, cardiology, oncology and immunology, which will be sold under Biocon′s brand in Singapore and Thailand, it added.

DKSH will manage marketing and sales as well as logistics for Biocon Pharma, helping drive sales growth through its capabilities and strengths in the medical and pharmacy channels. The agreement is in line with Biocon′s strategy for expansion of its generic formulations business through licensing of its drug products in multiple markets.